Abstract

Analysis of off-target editing is an important aspect of the development of safe nuclease-based genome editing therapeutics. in vivo assessment of nuclease off-target activity has primarily been indirect (based on discovery in vitro, in cells or via computational prediction) or through ChIP-based detection of double-strand break (DSB) DNA repair factors, which can be cumbersome. Herein we describe GUIDE-tag, which enables one-step, off-target genome editing analysis in mouse liver and lung. The GUIDE-tag system utilizes tethering between the Cas9 nuclease and the DNA donor to increase the capture rate of nuclease-mediated DSBs and UMI incorporation via Tn5 tagmentation to avoid PCR bias. These components can be delivered as SpyCas9-mSA ribonucleoprotein complexes and biotin-dsDNA donor for in vivo editing analysis. GUIDE-tag enables detection of off-target sites where editing rates are ≥ 0.2%. UDiTaS analysis utilizing the same tagmented genomic DNA detects low frequency translocation events with off-target sites and large deletions in vivo. The SpyCas9-mSA and biotin-dsDNA system provides a method to capture DSB loci in vivo in a variety of tissues with a workflow that is amenable to analysis of gross genomic alterations that are associated with genome editing.

In vivo assessment of nuclease off-target activity has primarily been indirect or through ChIP-based detection of double-strand break DNA repair factors, which can be cumbersome. Here, the authors show that GUIDE-tag, enables one-step off-target genome editing analysis in mouse liver and lung.

Details

Title
Genome-wide detection of CRISPR editing in vivo using GUIDE-tag
Author
Liang Shun-Qing 1 ; Liu Pengpeng 2 ; Smith, Jordan L 1 ; Mintzer, Esther 2 ; Maitland, Stacy 2 ; Dong Xiaolong 1 ; Yang, Qiyuan 2 ; Lee, Jonathan 1   VIAFID ORCID Logo  ; Haynes, Cole M 2   VIAFID ORCID Logo  ; Zhu, Lihua Julie 3   VIAFID ORCID Logo  ; Watts, Jonathan K 1   VIAFID ORCID Logo  ; Sontheimer, Erik J 4   VIAFID ORCID Logo  ; Wolfe, Scot A 5   VIAFID ORCID Logo  ; Xue Wen 6   VIAFID ORCID Logo 

 University of Massachusetts Medical School, RNA Therapeutics Institute, Worcester, USA (GRID:grid.168645.8) (ISNI:0000 0001 0742 0364) 
 University of Massachusetts Medical School, Department of Molecular, Cell and Cancer Biology, Worcester, USA (GRID:grid.168645.8) (ISNI:0000 0001 0742 0364) 
 University of Massachusetts Medical School, Department of Molecular, Cell and Cancer Biology, Worcester, USA (GRID:grid.168645.8) (ISNI:0000 0001 0742 0364); University of Massachusetts Medical School, Department of Molecular Medicine, Worcester, USA (GRID:grid.168645.8) (ISNI:0000 0001 0742 0364); University of Massachusetts Medical School, Program in Bioinformatics and Integrative Biology, Worcester, USA (GRID:grid.168645.8) (ISNI:0000 0001 0742 0364) 
 University of Massachusetts Medical School, RNA Therapeutics Institute, Worcester, USA (GRID:grid.168645.8) (ISNI:0000 0001 0742 0364); University of Massachusetts Medical School, Department of Molecular Medicine, Worcester, USA (GRID:grid.168645.8) (ISNI:0000 0001 0742 0364); University of Massachusetts Medical School, Li Weibo Institute for Rare Diseases Research, Worcester, USA (GRID:grid.168645.8) (ISNI:0000 0001 0742 0364) 
 University of Massachusetts Medical School, Department of Molecular, Cell and Cancer Biology, Worcester, USA (GRID:grid.168645.8) (ISNI:0000 0001 0742 0364); University of Massachusetts Medical School, Li Weibo Institute for Rare Diseases Research, Worcester, USA (GRID:grid.168645.8) (ISNI:0000 0001 0742 0364) 
 University of Massachusetts Medical School, RNA Therapeutics Institute, Worcester, USA (GRID:grid.168645.8) (ISNI:0000 0001 0742 0364); University of Massachusetts Medical School, Department of Molecular, Cell and Cancer Biology, Worcester, USA (GRID:grid.168645.8) (ISNI:0000 0001 0742 0364); University of Massachusetts Medical School, Department of Molecular Medicine, Worcester, USA (GRID:grid.168645.8) (ISNI:0000 0001 0742 0364); University of Massachusetts Medical School, Li Weibo Institute for Rare Diseases Research, Worcester, USA (GRID:grid.168645.8) (ISNI:0000 0001 0742 0364) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2621804899
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.